Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Publications

Benefits of aldosterone receptor antagonism in chronic kidney disease: the BARACK-D RCT.

Hobbs FDR. et al, (2025), Health Technol Assess, 29, 1 - 130

Low-dose spironolactone and cardiovascular outcomes in moderate stage chronic kidney disease: a randomized controlled trial.

Hobbs FDR. et al, (2024), Nat Med

Correction: PET-CT-guided, symptom-based, patient-initiated surveillance versus clinical follow-up in head neck cancer patients (PETNECK2): study protocol for a multicentre feasibility study and non-inferiority, randomised, phase III trial.

Nankivell P. et al, (2024), BMC Cancer, 24

Systematic review of patients' and healthcare professionals' views on patient-initiated follow-up in treated cancer patients.

Dretzke J. et al, (2023), Cancer Med, 12, 16531 - 16547

Proton Beam Therapy in Breast Cancer Patients: The UK PARABLE Trial is Recruiting.

Kirby AM. et al, (2023), Clin Oncol (R Coll Radiol), 35, 347 - 350

Individualised Estimation of Quality-adjusted Survival Benefit and Cost-effectiveness of Proton Beam Therapy in Intermediate-stage Hodgkin Lymphoma.

Jones DA. et al, (2023), Clin Oncol (R Coll Radiol), 35, 301 - 310

Protocol for the TRANSLATE prospective, multi-centre, randomised clinical trial.

Bryant RJ. et al, (2023), BJU Int

TORPEdO: A phase III trial of intensity-modulated proton beam therapy versus intensity-modulated radiotherapy for multi-toxicity reduction in oropharyngeal cancer.

Thomson DJ. et al, (2023), Clin Transl Radiat Oncol, 38, 147 - 154

Correction: Benefits of Aldosterone Receptor Antagonism in Chronic Kidney Disease (BARACK D) trial-a multi-centre, prospective, randomised, open, blinded end-point, 36-month study of 2,616 patients within primary care with stage 3b chronic kidney disease to compare the efficacy of spironolactone 25 mg once daily in addition to routine care on mortality and cardiovascular outcomes versus routine care alone: study protocol for a randomized controlled trial.

Hill NR. et al, (2022), Trials, 23

P095: Personalised Modelling of Quality-Adjusted Survival Benefit and Cost-Effectiveness of using Proton Beam Therapy inthe Treatment of Intermediate-Stage Hodgkin Lymphoma in England

Jones D. et al, (2022), HemaSphere, 6, 43 - 44

Quality of life in older adults with chronic kidney disease and transient changes in renal function: findings from the Oxford Renal Cohort

HOBBS F. et al, (2022), PLoS One

Small area estimates of BMI by age, sex and lower tier local authority (England)

Amies-Cull B. et al, (2022)

Clinicians' Views of Patient-initiated Follow-up in Head and Neck Cancer: a Qualitative Study to Inform the PETNECK2 Trial.

Lorenc A. et al, (2022), Clin Oncol (R Coll Radiol), 34, 230 - 240

The costs of bipolar disorder in the United Kingdom.

Simon J. et al, (2021), Brain Behav, 11

Survival, Dependency, and Health-Related Quality of Life in Patients With Ruptured Intracranial Aneurysm: 10-Year Follow-up of the United Kingdom Cohort of the International Subarachnoid Aneurysm Trial.

Hua X. et al, (2021), Neurosurgery, 88, 252 - 260

Survival, Dependency, and Health-Related Quality of Life in Patients With Ruptured Intracranial Aneurysm: 10-Year Follow-up of the United Kingdom Cohort of the International Subarachnoid Aneurysm Trial (ISAT)

Hua X. et al, (2021), NEUROSURGERY, 89, S81 - S81

Improving outcomes for women diagnosed with early breast cancer through Adherence to adjuvant endocrine therapy (SWEET)

Sharp L. et al, (2020), BREAST CANCER RESEARCH AND TREATMENT, 180, 544 - 545

Correction: Economic analysis of oral dexamethasone for symptom relief of sore throat: the UK TOAST study.

(2019), BMJ Open, 9

A randomised controlled trial of Partial prostate Ablation versus Radical prosTatectomy (PART) in intermediate risk, unilateral clinically localised prostate cancer: a feasibility study

Hamdy FC. et al, (2018), Health Technology Assesment, 22, 1 - 96

Partial ablation versus radical prostatectomy in intermediate-risk prostate cancer: the PART feasibility RCT.

Hamdy FC. et al, (2018), Health Technol Assess, 22, 1 - 96

Load More

1
2
3
4
5

Include forthcoming?